() NOVARTIS

Signifor@

diaspartate)

Excipients: Mannitol tartaric acid sodium droxide, water for injections.

Pharmaceutical form and quantity of active substance per unit

- Solution for injection in ampoules. Clear. colourless solution.
- Each 1 ml ampoule contains 0.3 mg pasire-
- Each 1 ml ampoule contains 0.6 mg pasire-

Each 1 ml ampoule contains 0.9 mg pasire-

ndications/Potential uses

Treatment of patients with Cushing's disease when all non-drug treatment alternatives according to current standards have been exhausted.

Dosage/Administration

The recommended initial dose of Signifor is sub cutaneous (s.c.) injection of 0.6 mg twice daily. Hypocortisolism

clinically significant reduction in urinary free corwith Signifor for as long as they benefit from it. hypocortisolism.

Maximum UFC reduction is typically seen after Glucose metabolism two months of treatment.

Special patient populations Patients with renal impairment Dose adjustment is not required in patients wit impaired renal function.

Patients with hepatic impairment ate hepatic impairment (Child-Pugh B) is 0.3 mg cose deregulation is higher in patients with pretwice daily. The maximum recommended dose diabetic metabolic status or frank diabetes. for patients with moderate hepatic impairment is Glycaemic status (fasting blood glucose and with uncontrolled or significant cardiac dis-0.6 mg twice daily. Signifor should not be used HbA1c) should be assessed before starting Pugh C) (see "Contraindications").

Children and adolescents

adolescents have not been studied.

Iderly patients

Data on the use of Signifor in patients over 6 years of age are limited. There is no evidence that dose adjustment is required in elderly pa-

Contraindications

Hypersensitivity to the active substance or any of the excipients. Severe hepatic impairment (Child-Pugh C

Warnings and precautions

to transient hypercortisolism with the signs and during pasireotide therapy. One month after starting treatment with Signifor. weakness, fatigue, anorexia, nausea, vomiting. Cardiovascular events as long as the 0.6 mg dose is well tolerated by generally within the first two months of treat-history of clinically significant bradycardia, acute thereafter if clinically indicated the patient. Patients who have not responded to ment. Depending on the clinical situation, it may myocardial infarction or Mobitz type II block, con-Patients with elevated transaminase levels should nifor with antiarrhythmic agents or drugs that Signifor after two months of treatment should be be necessary to discontinue treatment, reduce gestive heart failure (NYHA class III or IV), unsta have a second liver function test to confirm the may prolong the OT interval (see "Warnings and considered for discontinuation. Patients with a the dose of Signifor and/or give low-dose, short- ble angina, ventricular tachycardia or ventricular results. If levels are elevated, liver function tests precautions").

Dose adjustment is not required in patients with insulin and incretin hormones (i.e. glucagon-like clinical studies in other patient populations.

in patients with severe hepatic impairment (Child-treatment and regularly monitored during treatment. Self-monitoring of blood glucose and FPG/ HbA1c levels should be done every week for The efficacy and safety of use in children and the first two to three months of treatment and periodically thereafter at clinically appropriate intervals FPG levels should be monitored for three weeks, and HbA1c levels for three months after the end of treatment

> If hyperglycaemia occurs, initiation or adjustment of hyperglycaemia therapy with incretins. insulin secretagogues and/or insulin is indicated. If hyperglycaemia cannot be controlled despite appropriate medical measures, the Signifor dose Liver function tests should be reduced or treatment discontinued. Transient mild elevations in aminotransferases Cushing's disease patients with poor glycaemic are commonly observed in healthy subjects and control (defined as HbA1c values >8% on antidi- patients treated with pasireotide. Concurrent elabetic therapy) are at higher risk of developing evation of alanine aminotransferase (ALT) >3 \times severe hyperglycaemia and associated compli-upper limit of normal (ULN) and bilirubin >2 ×

fibrillation – must be carefully monitored. It may should be performed frequently until the patient Anticipated interactions affecting other drugs tisol [UFC] and improvement in signs and symp. Patients should be regularly monitored and intoms of the disease should continue treatment formed about the symptoms associated with as beta blockers, calcium channel blockers or Treatment with pasireotide should be discontinagents to control electrolyte balance

Pasireotide was shown to prolong the OT interval of clinically significant hepatic impairment, or in Pasireotide appears to be a substrate of ef-Changes in glucose regulation are likely during in the ECG in a study in healthy volunteers. The the event of an increase in aspartate aminotrans- flux transporter Pgp (P-glycoprotein). However, treatment of Cushing's disease with pasireotide. clinical significance of this prolongation is un-ferase (AST) or ALT >5 × ULN or an increase in pasireotide is not an inducer of Pgp at clini-Hyperglycaemia, raised fasting blood glucose, known. A OTCF value of >500 ms was measured ALT >3 × ULN with concurrent bilirubin elevation cally relevant concentrations. Pasireotide is not an increase in HbA1c and, less often, hypogly- in two of 201 patients. These episodes were >2 × ULN. Following discontinuation of treat- a substrate of the efflux transporter breast caemia have been observed in clinical studies sporadic and occurred once only with no clinical ment, patients should be monitored until recover cancer resistance protein (BCRP), nor of the of pasireotide. The development of hypergly-consequence. Episodes of torsade de pointes ery. Treatment should not be restarted. caemia correlates with decreased secretion of were not observed, either in these studies or in Active substance: Pasireotide (as pasireotide mild hepatic impairment (Child-Pugh A). The recommended initial dose for patients with moder-

with congenital long OT syndrome.

ease, including recent myocardial infarction, congestive heart failure, unstable angina or clinically significant bradycardia. taking antiarrhythmics or other substances

with known potential for OT prolongation. with hypokalaemia and/or hypomagnesaemia. Pituitary hormones

periodically during treatment.

cations (e.g. ketoacidosis). In patients with poor ULN has been observed in rare cases. All cases Fertility Signifor dose may be temporarily reduced. Dose sion of adrenocorticotropic hormone (ACTH) glycaemic control, diabetes management and of concurrent elevation were identified within 10. The effect of pasireotide on human fertility is reduction in 0.3 mg steps twice daily is recom-secretion. Rapid suppression of ACTH may lead liver function test results returned to baseline af- fertility might be reduced. ter interruption of treatment. Monitoring of liver patients should be evaluated for clinical benefit. hypotension, hyponatraemia or hypoglycaemia Bradycardia has been observed during treatment function is therefore recommended before and Interactions A dose increase to 0.9 me (twice daily) may be and even Addisonian crisis. Cases of hypocorti- with pasireotide. Patients with cardiac disease during the first two to three months of treatment. No clinical studies have been performed to a considered in those responding to treatment, solism have been reported in the phase III study, and/or risk factors for bradycardia – such as a with Signifor (after 1, 2, 4, 8 and 12 weeks), and sess drug-drug interaction potential.

ued if patients develop jaundice or other signs or inducer of CYP450 in vitro.

Gallstone formation is a known adverse effect of long-term treatment with somatostatin analogues and has been frequently observed in clinical studies of pasireotide. Ultrasound examination of the gallbladder is therefore recommended before treatment with Signifor and then at 6- to 12month intervals. The occurrence of gallstones in Signifor-treated patients is largely asymptomatic: symptomatic stones should be managed according to clinical practice.

terval is advisable and a baseline ECG is recom- common sequela of transsphenoidal surgery and effect. Caution is required when administering mended before starting treatment with Signifor even more common after pituitary radiotherapy. pasireotide concomitantly with drugs that have a and as clinically indicated. Hypokalaemia or Cushing's disease patients with persistent or low therapeutic index and are metabolized mainly hypomagnesaemia must be corrected before recurrent disease may therefore present with by CYP3A4 (e.g. quinidine, terfenadine). reatment with Signifor and should be monitored deficiency of one or more pituitary hormones. In dogs, pasireotide has been found to decrease As the pharmacological effect of pasireotide the blood level of ciclosporin by reducing its inmimics that of somatostatin, inhibition of other testinal absorption. It is unknown whether such pituitary hormones in addition to ACTH cannot interaction occurs in humans. Ciclosporin dose be ruled out. Pituitary function (e.g. TSH/free T., adjustment may therefore be necessary when GH/IGF-1) should therefore be monitored before coadministering pasireotide and ciclosporin. starting treatment with Signifor and periodically Coadministration of bromocriptine with somatoduring treatment, as clinically appropriate. statin analogues may increase the availability of

Caution is required when coadministering Sig

Pasireotide has moderate protein binding, is met- Breastfeeding

influx transporters organic cation transporter 1 (OCT1), organic anion-transporting polypeptides (OATP) 1B1, 1B3 or 2B1. At clinically relevant concentrations, pasireotide is not expected to inhibit UGT1A1 (uridine diphosphate glucuronosyltransferase 1A1), influx transporters OATP 1B1 or 1B3, efflux transporters Pgp, BCRP, MRP2 (multiresistance protein 2) or BSEP (bile

salt export pump). Limited published data suggest that somatostatin analogues might indirectly reduce metabolic clearance of compounds metabolized by CYP450 enzymes by suppressing growth hormone secretion. Available data cannot exclude the possibil-Monitoring for a possible effect on the OTc in- Deficiency of pituitary-secreted hormones is a ity that pasireotide may exert such an indirect

bromocriptine. The possibility cannot be excluded that pasireotide may exert such an effect.

Pregnancy/Breastfeeding

There are no adequate and well-controlled studies in pregnant women. Studies in rats and rabbits have shown evidence of fetal damage by pasireotide at therapeutic exposure levels (see "Preclinical data"). Reproductive toxicity studies in animals are not always indicative of the response in humans. Signifor should only be used during pregnancy under compelling circum-

human milk. Studies in rats have shown excretion

Common: Type 2 diabetes mellitus, decreased appetite. Nervous system disorders Common: Headache. Cardiac disorders

of pasireotide in milk (see "Preclinical data"). As Gastrointestinal disorders patients should not breastfeed during treatment pain.

Effects on ability to drive and use ma-

Pasireotide has no effect on the ability to drive or use machines

Adverse effects

with Signifor

chines

A total of 201 Cushing's disease patients received treatment with Signifor in the phase II and III studies. The tolerability profile is consistent cept for the occurrence of hypocortisolism and tions degree of hyperglycaemia. The data described below relate to 162 Cush- Investigations mg or 0.9 mg twice daily in the phase III study. creased

2.5% of patients, respectively, and were mostly longed related to hyperglycaemia. The most common ADRs (incidence >10%) were diarrhoea, nausea. Overdose The following adverse effects were reported in Doses up clinical studies of pasireotide, and are listed be- to 2.1 mg twice daily have been administered to Frequencies were defined as follows: very com-frequent adverse effect. mon ($\geq 1/10$), common ($\geq 1/100$ to < 1/10), uncommon ($\geq 1/1000$ to < 1/100).

Endocrine disorders Common: Adrenocortical insufficiency.

Metabolism and nutrition disorders Very common: Hyperglycaemia, diabetes mel-

Common: Vomiting, upper abdominal pain.

Hepatobiliary disorders Very common: Cholelithiasis. Skin and subcutaneous tissue disorders

Common: Alopecia. Vascular disorders Common: Hypotension.

Blood and lymphatic disorders Uncommon: Anaemia.

with that of the somatostatin analogue class, ex- General disorders and administration site condi-

Verv common: Injection site reactions, fatigue.

fects were grade 1 or 2 (57.4%). Grade 3 and lipase increased, blood glucose increased, tide. Metformin had no material effect. 4 adverse effects were observed in 35.8% and blood amvlase increased, prothrombin time pro-

abdominal pain, cholelithiasis, hyperglycaemia, No cases of overdosage have been reported in diabetes mellitus, fatigue and increased HbA1c. patients receiving pasireotide subcutaneously.

low according to MedDRA terminology. healthy volunteers, leading to diarrhoea as a very

Adverse effects are ranked in order of decreas- ated, as dictated by the patient's clinical status, ing seriousness within each frequency grouping. until resolution of the symptoms.

Properties/Actions

ATC code: H01CB05 Mechanism of action Pasireotide (cyclohexapeptide) is a somatostatin analogue that binds with high affinity to human somatostatin receptor subtypes hsst 1, 2, 3 and 5.

Pharmacodynamic properties *Common*: Sinus bradycardia, OT prolongation. In vitro studies have shown that corticotroph twice daily.

inhibition of ACTH secretion.

Glucose metabolism

In a phase I study in healthy volunteers, pasireotide was administered with or without oral antidiabetics (metformin, nateglinide, vildagliptin, liraglutide) for 7 days. An oral glucose tolerance test was performed before the start of treatment and on day 7. After the first pasireotide dose. glucose AUC increased by more than 100% relative to baseline in all 5 study arms. On day 7 the difference from baseline was 69% without antidiabetics, compared to 60% on comedication with ing's disease patients treated with Signifor 0.6 Very common: Glycosylated haemoglobin in-metformin, 49% on nateglinide, 38% on vildagliptin and 19% on liraglutide. This correlated with The frequency and severity of adverse effects Common: Gamma-glutamyltransferase in- a 79% decrease in insulin secretion, which was were similar in the two dose groups. Most ef-

Cardiac electrophysiology

sessed in two open-label, controlled, cross-over were based on the randomized dose groups. dedicated QT studies. In both studies an effect of Baseline characteristics were balanced between Pharmacokinetics pasireotide on the QT interval was observed. One the two dose groups, except for a large differ- Absorption of the studies, with a dose of 1950 µg twice dai-ence in mean 24-hour UFC (1156 nmol/24 h for Pasireotide is rapidly and completely absorbed QTcF value of 17.5 ms (90% confidence inter-for the 0.9 mg twice daily group; normal range tions are reached within 0.25-0.5 hours. Cmar and val [Cl]: 15.53; 19.38). The other study found 30-145 nmol/24 h). maximum mean placebo-adjusted QTcl values of After 6 months. normalization of mean UFC lev- both single and multiple dosing. both doses there was a reduction in heart rate, mg twice daily treatment groups. with a maximum difference from placebo ob-

Clinical efficacy

If response was not achieved after 6 months and 12. or not maintained during the open-label treat- A significant reduction in median UFC levels was in urine.

of patients in each arm who achieved normaliza- Clinically meaningful decreases in sitting systolic compared to younger patients. tion of mean 24-hour urinary free cortisol levels and diastolic blood pressure. BMI and total cho-(UFC <ULN) after 6 months of treatment and who lesterol were observed in both dose groups after No studies have been performed in children. did not have a dose increase (relative to rand- 6 months. Similar trends were observed after 12 Patients with renal impairment ary endpoints included changes from baseline also decreasing at that time point. in 24-hour UFC. plasma ACTH, serum cortisol After 6 months a third of patients in both dose levels. clinical signs and symptoms of Cushing's groups showed favourable changes in facial disease and health-related quality of life (HRQL) rubor, supraclavicular and dorsal fat pads and The effect of Signifor on the QT interval was as as measured by the CushingQoL. All analyses median global CushingQoL scores.

y, measured a maximum mean placebo-adjusted the 0.6 mg twice daily group and 781 nmol/24 h after SC injection, and peak plasma concentra-

13.19 ms (90% Cl: 11.38; 15.01) and 16.12 ms els was observed in 14.6% (95% Cl 7.0 to 22.3) that appropriate supportive treatment be initi-(90% CI: 14.30: 17.95 ms), respectively, at the and 26.3% (95% CI 16.6 to 35.9) of patients, doses of 600 µg and 1950 µg twice daily. At respectively, in the pasireotide 0.6 mg and 0.9

served after 1 hour for pasireotide 600 µg twice the 0.9 mg twice daily dose group, as the lower daily (-10.39 bpm) and after 30 minutes for pasireotide 1950 µg twice daily (-14.91 bpm). 15% boundary. However, this response in the 0.9 mg twice daily group seemed to be higher for a double-blind multicentre randomized phase patients with lower mean UFC at baseline. In both Ill study, 162 patients with persistent or recurrent dose groups Signifor led to a rapid and marked Metabolism

tumour cells from Cushing's disease patients. After three months of treatment, patients who groups, respectively. The controlled and partially half-life (t, approximately 12 hours) in healthy a risk to the breastfed child cannot be excluded. Very common: Diarrhoea, nausea, abdominal display high expression of hsst5, whereas other had a mean 24-hour UFC <2 × ULN and values at controlled response rates after 6 months repre- volunteers. recentor subtypes are either not expressed or or below baseline continued blinded treatment at sented 34% (0.6 mg twice daily) and 41% (0.9 Flimination are expressed at lower levels. Pasireotide binds the randomized dose until month 6. Patients who mg twice daily) of randomized patients (controland activates the hsst receptors of the cortico-did not meet these criteria were unblinded and led: UFC $\leq 1.0 \times$ ULN, partially controlled: UFC additional 6-month open-label treatment period. likely (90%) to remain uncontrolled at months 6

> ment period, the subcutaneous dose could be noted in both treatment arms. After 6 months the increased by 0.3 mg twice daily. The maximum median percentage reduction in UFC levels was Special patient populations injected dose was 1.2 mg s.c. twice daily. The 47.9% in both treatment groups (0.6 mg and 0.9 Elderly patients dose could be reduced in steps of 0.3 mg twice mg twice daily): after 12 months the percentage Data on Cushing's disease patients older than 65

AUC are approximately dose-proportional after

Pasireotide has a volume of distribution (V /F of >100 litres. Pasireotide is primarily located in the plasma (91%). Plasma protein binding is moderate (88%) and independent of concentra-

Pasireotide is likely to be a substrate of Pgp; it has not been studied for ability to penetrate the cerebrospinal fluid.

clearance (biliary excretion) and only to a small tronhs in ACTH-producing adenomas, resulting in the dose was increased by 0.3 mg twice daily. >1.0 × ULN, but ≥50% decrease in UFC). Pa-After 6 months of treatment, patients started an tients uncontrolled at both months 1 and 2 were belled nasireotide was recovered over the first 10 days post dosing, including $48.3 \pm 8.16\%$ of the radioactivity in faeces and $7.63 \pm 2.03\%$

daily at any time for intolerability. UFC reduction was 67.6% and 62.4% for the 0.6 years are limited but do not suggest any clini-The primary efficacy endpoint was the proportion mg and 0.9 mg twice daily groups, respectively. cally significant differences in safety and efficacy

omized initial dose) during this period. Second months, with the addition of serum triglycerides Clinical studies have not been performed in pa tients with impaired renal function.

Patients with hepatic impairment

In a clinical study in subjects with impaired hepatic function (Child-Pugh A, B and C), only subjects with moderate to severe hepatic impairment (Child-Pugh B and C) showed significantly elevated exposures compared to patients with normal hepatic function. After correction for covariate effect (age, BMI and albumin), AUC, was increased by 60% to 79%. C increased by 67% to 69%, and CL/F decreased by 37% and 44% compared to the control group.

Population PK analyses of Signifor suggest that race and gender do not influence PK param-

Non-clinical safety studies included safety pharmacology, repeated-dose toxicity, genotoxicity and carcinogenicity, and reproductive and developmental toxicity. Most findings in the repeated toxicity studies were reversible and attributable Cushing's disease following adenoma resection decrease in mean UFC after 1 month, which was Pasireotide was shown to be highly metabolically to the pharmacology of pasireotide. The main and patients for whom surgery was not indicated maintained throughout the treatment period. The stable in human liver and kidney microsomes. findings were lower pituitary weight and soma-Somatostatin receptors are expressed in many or who refused surgery were treated for 12 response rate after 12 months was comparable Pasireotide displays low clearance in healthy vol- totroph eosinophilia (rat) or increased pituitary tissues, as well as in neuroendocrine turnours, months with either 0.6 mg or 0.9 mg pasireotide to that after 6 months, amounting to 13.4% and unteers (6.7 litres/hour) and Cushing's disease acidophilia (monkey), inhibition of body weight 25.0% in the 0.6 mg and 0.9 mg twice daily dose patients (3.8 litres/hour). It has a long effective gain and growth (including bone growth in ro-

no adverse effects on respiratory or cardiovascular functions. Decreases in general and behav- Other information ioural activity were observed in mice at a dose of Incompatibilities surface area.

Pasireotide was found non-genotoxic in two in mixed with other medicinal products. vitro genotoxicity tests (Ames test and chromo- Administration mg/kg, approximately 250 times the maximum Signifor subcutaneously. recommended therapeutic human dose (MRHD). Repeated injections within a short period at the based on surface area.

In embryo-fetal development studies in rats and and waistline). rabbits, pasireotide was not teratogenic at maternally toxic doses (corresponding to 10 [rat] Do not use after the expiry date (= EXP) printed and 1 Irabbit1 mg/kg/day) leading to exposures on the pack. (AUC....) 145 [rat] and 6.5 [rabbit] times exposure at the MRHD. At 10 mg/kg/day in rats, the Special precautions for storage frequency of early/total resorptions and malrotated limbs was increased. At 5 mg/kg/day in rabbits (corresponding to 40 times exposure at MRHD), increased abortions, reduced fetal Instructions for use and handling observed. Reduced fetal weight and ensuing glass ampoule. Pasireotide is excreted in milk. Retardation of the use of Signifor from the ampoule. physiological growth in the offspring was seen at Special precautions for disposal pups exposed to pasireotide were comparable ments to controls, indicating reversibility. Pasireotide did not affect fertility in male rats at doses up to Pack sizes face area). Animal studies showed that fertility poules (5 boxes containing 6 ampoules)

dents), reduced liver weight and increased liver in female rats decreased at daily doses of 0.1 Ampoules containing 0.6 mg; packs of 30 amenzyme levels (rodents), and reduced cellularity mg/kg/day (0.6 times MRHD, based on surface poules (5 boxes containing 6 ampoules) of haematopojetic organs. The effects in non- area), as shown by decreased numbers of live Ampoules containing 0.9 mg; packs of 30 amclinical studies were generally observed at ex- conceptions and implantation sites. A reduced poules (5 boxes containing 6 ampoules) posures similar to or greater than the maximum number of corpora lutea and abnormal cycles Other country specific pack sizes, as applicable, or if the liquid looks cloudy or contains partiexposure to human therapeutic doses. or acyclicity were observed at 1 mg/kg/day (5 In safety pharmacology studies, pasireotide had times MRHD, based on surface area).

12 mg/kg, equivalent to 32 times the maximum No compatibility data with other products have recommended human dose (MRHD), based on been generated. Pasireotide solution for injection is to be used undiluted and must not be

some aberration test in human peripheral lym- Signifor is administered subcutaneously by selfphocytes). Pasireotide was not genotoxic in an injection. Patients must be instructed by the phyin vivo rat micronucleus test at doses up to 50 sician or healthcare professional how to inject

same or a nearby injection site should be avoid-Carcinogenicity studies conducted in rats and ed. Sites showing signs of irritation or inflammatransgenic mice did not identify any carcinogenic tion should be avoided. Preferred injection sites are the thighs and abdomen (excluding the navel

Keep out of the reach of children. Store in the original pack and protect from light. The injection site is the place on your body Do not store above 30°C.

weights and ensuing skeletal variations were The solution for injection is supplied in a 1 ml

day (6.5 times exposure at MRHD). In a pre- and the patient should be instructed by a physician or subcutaneous injection. Avoid soreness and skin postnatal study in rats pasireotide had no effect other healthcare professional how to use Signifor irritation by choosing a different site from the on labour or delivery at doses up to 10 mg/kg/ from the ampoule. Refer to the package leaflet previous one for each injection. You should also day (52 times MRHD, based on surface area). (patient information) for further instructions on avoid injections at sites that are sore or where

2 mg/kg/day (10 times MRHD, based on surface Any unused product or waste material should area). After weaning, body weight gains in the rat be disposed of in accordance with local require-

Instructions for use of Signifor

Signifor should be administered using sterile disposable syringes and injection needles. Your doctor or nurse will have instructed you on how to use Signifor ampules. However, before using the ampule, please read the following inormation carefully. If you are not sure about how to give the injection or you have any questions. please ask your doctor or nurse for help. Store Signifor ampules according to the storage condition listed on the box.

Important safety information Caution: Keep the ampules out of the reach of children. What do you need to give yourself a subcutaneous injection

One Signifor ampule

- . Alcohol wipes or similar
- 3. One sterile syringe
- One sterile needle
- A sharps container or other rigid closed disposal container

The injection site

where you are going to give yourself the injection. Signifor is intended for subcutaneous use. This means that it is injected through a short needle into the fatty tissue just under the skin. delayed ossification were seen at 1 mg/kg/ To ensure proper administration of the product. The thighs and the abdomen are good areas for the skin is irritated.

Getting started

tion, carefully follow the steps below:Wash your hands thoroughly with soap and water. Always use a new disposable needle and 10 mg/kg/day (52 times MRHD, based on sur- Ampoules containing 0.3 mg; packs of 30 am- syringe every time you give yourself an injec-

- share needles and syringes with someone else.
- spect the ampule. DO NOT USE if it is broken cles. In all these cases, return the entire pack to the pharmacy.

Check the expiry date and the dose: Check the expiry date (EXP) which is stated on the carton and ampule label and check that it is the dose your doctor has prescribed for you. DO NOT USE if the medicine has expired or if the dose is incorrect. In both these cases, return the entire pack to the pharmacy. How to inject Signifor

> Before you proceed to Step 1. clean the injection site you have selected with an alcohol swab.

Step 1: Signifor solution for injection is filled in a snap-off ampule. Tap the ampule with your finger in order to make sure there is no liquid in the lid when you open the ampule.

Step 2: Open it by snapping off the top of the ampule at the line marked on the ampule neck. Once open, put the ampule upright on a clean, flat surface.

Step 3: Take the sterile syringe and attach the needle to it. Remove the cover from the needle.


Step 4: Put the needle into the ampule and pull the plunger to draw the entire contents of the ampule into the syringe.

Step 5: Hold the syringe in one hand between two fingers with your thumb at the bottom of the plunger. Tap the svringe with your fingers to get rid of air bubbles. Make sure there is no air bubble in the syringe by pressing the plunger until the first drop appears on the tip of the needle. Do not let the needle Novartis Pharma Stein AG, Stein, Switzerland touch anything. You are now ready to inject.

Step 6: Gently pinch the land skin at the injection site 45 degrees (as shown in the picture) insert it into the injection site. Pull slightly on the plunger to check that a blood vessel has not been punctured. If you see blood in the syringe. remove the needle and insert it into a different injection site.

Step 7: Always keeping vour skin pinched, slowly press down the plunger as far as it will go until all the solution is iniected. Keep the plunger pressed down and hold the syringe in place for 5 seconds.

Step 8: Slowly release the skin fold and gently pull the needle out. Put the cover back on the needle.



This is a medicament

- A medicament is a product which affects your health, and its consumption contrary to instructions is dangerous for you.
- Follow strictly the doctor's prescription, the method of use and the instructions of the pharmacist who sold the medicament.
- The doctor and the pharmacist are experts in medicine, its benefits and risks.
- Do not by yourself interrupt the period of treatment prescribed for you
- Do not repeat the same prescription without consulting your doctor.

Keep medicaments out of reach of children

Council of Arab Health Ministers Jnion of Arab Pharmacists



used syringe and needle immediately in a sharps container or other rigid closed disposal container. Any unused product or waste material should be disposed of in accordance with local requirements

Step 9: Dispose of the

Manufacturer

Marketing authorization holder

Novartis Pharma Schweiz AG, Risch, Switzer-

 R = registered trademark
Novartis Pharma AG. Basle, Switzerland



